Literature DB >> 12853712

A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy.

Craig M Jackson1, M Peter Esnouf, Tomas L Lindahl.   

Abstract

The Quick prothrombin time is the most common clotting test performed, principally for monitoring oral anticoagulant therapy. The International Normalized Ratio (INR) for comparing patient results from prothrombin time measurements and the International Standardized Index (ISI) for achieving greater consistency of results using different thromboplastins have made it possible to compare the results of vitamin K antagonist drug therapy that was impossible before the introduction of the INR and ISI. However, INR values obtained from the same patient plasma sample using different thromboplastins are significantly different. This is so even when the thromboplastins have nearly the same ISI values. We suggest that investigation of patient-specific differences can provide a means by which the INR discrepancies can be identified and understood and thus lead to better methods for monitoring oral anticoagulant therapy. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853712     DOI: 10.1159/000071641

Source DB:  PubMed          Journal:  Pathophysiol Haemost Thromb        ISSN: 1424-8832


  3 in total

Review 1.  Algorithm for anticoagulation management in geriatric hip fracture patients--Surgeons save Blood.

Authors:  M A Wendl-Soeldner; C W I Moll; C Kammerlander; M Gosch; T Roth
Journal:  Z Gerontol Geriatr       Date:  2014-02       Impact factor: 1.281

2.  A re-appraisal of warfarin control in the treatment of deep vein thrombosis and / or pulmonary embolism.

Authors:  C Amiwero; I A Campbell; R J Prescott
Journal:  Afr Health Sci       Date:  2009-09       Impact factor: 0.927

3.  Evaluation of the Steelex M600H coagulometer prothrombin time-international normalized ratio assay with Steelex test reagents.

Authors:  Yasemin U Budak; Kağan Huysal; Murat Polat; Gülsevil Tarakçi; Hakan Uçar
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.